HSP90AA1 and colonic neoplasm: Intriguingly, our results showed that knockdown of CDC37 caused a moderate decrease in the basal levels of ERK activation and reactivation of ERK after treatment with AUY922, suggesting that CDC37 is able to stabilize mutant BRAF independently of HSP90 in colon cancer cells [23].